Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Recurrent Ovarian or Primary Peritoneal Carcinoma
NCT00082212Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2004
- Primary completion
- Jun 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in ovarian cancer and primary peritoneal carcinoma (PPC), sponsored by Eli Lilly and Company. Primary endpoint: Overall Response Rate. Started Nov 2004; status: terminated.
02
Drugs
cetuximab
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00082212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082212.